Comparing the current results to its competitors, Voyager Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -39.13 %, despite the revenue increase by the most of its competitors of 159.17 %, recorded in the same quarter.
Voyager Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates within the biopharmaceutical industry, facing competition from larger pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions and governmental agencies. Competitors include Lundbeck LLC; Merck & Co., Inc., in collaboration with Teijin Limited; Eisai Co., Ltd.; Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson; UCB S.A.; Bristol-Myers Squibb Company, in collaboration with Prothena Corporation plc; Ionis Pharmaceuticals, Inc., in collaboration with Biogen Inc.; Dewpoint Therapeutics, Inc.; WaveBreak Therapeutics, LLC; Molefy Pharma SL; 4D Molecular Therapeutics, Inc.; and Affini. The company’s programs, such as the anti-tau antibody program for Alzheimer's disease, tau silencing gene therapy for Alzheimer's disease, TDP-43 small molecule, and TRACER discovery platform, compete with therapies and technologies developed by these entities.
September 5, 2024
Voyager Therapeutics, Inc. has made significant strides in recent months, underscoring its commitment to advancing gene therapy through strategic partnerships and notable financial improvements. This article delves into Voyager s recent licensing agreement for next-generation capsids and examines the company’s return on average invested assets (ROI) as reported in its second quarter of 2024. Licensing Agreement for Next-Generation Capsids Voyager recently entered into a licensing agreement to further bolster its portfolio of gene therapies. The company announced that it would receive an upfront payment of $15 million, with the potential to earn up to $305 million through milestone payments and royalties a...
February 26, 2024
Friedreich s ataxia (FA) is a debilitating genetic neurodegenerative disorder that affects approximately 1 in 50,000 individuals worldwide. Characterized by progressive loss of coordination, muscle weakness, and impaired speech, FA significantly reduces the quality of life for affected individuals. However, a ray of hope shines through recent advancements in gene therapy research, as Voyager Therapeutics, in collaboration with Neurocrine Biosciences, announces the selection of a potential gene therapy development candidate for the treatment of FA. This groundbreaking discovery holds immense promise for the future management of this currently incurable condition.The Candidate s Innovative Approach:Voyager The...
February 20, 2024
Alzheimer s disease (AD) is a neurodegenerative disorder characterized by the accumulation of abnormal tau protein in the brain. Voyager Therapeutics, a leading biotechnology company focused on developing gene therapies for neurological diseases, reports robust preclinical activity in their tau silencing gene therapy program for Alzheimer s disease. Additionally, the company presents new data on the well-tolerated nature and favorable pharmacokinetics of their lead antibody, VY-TAU01, targeting pathological tau. These significant advancements pave the way for potential breakthroughs in treating AD, addressing the urgent need for effective therapies.Tau Silencing Gene Therapy:Voyager Therapeutics has been dil...
Passage Bio Inc's business model focuses on developing and commercializing innovative genetic therapies for rare, monogenic central nervous system disorders.
Sources:
Voyager Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Voyager Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
